Kalaris Therapeutics, Inc. filed 3 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-20. Between them they name 4 people, with 5 appointments and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Liisa Bayko, Chief Financial Officer, effective 2026-07-20
On July 16, 2026, the Board of Directors (the "Board") of Kalaris Therapeutics, Inc. (the "Company") appointed Liisa Bayko as Chief Financial Officer and Treasurer of the Company, effective as of July 20, 2026 (the "Effective Date").
Appointed: Liisa Bayko
In addition, Ms. Bayko will serve as the Company's principal financial officer.
Appointed: Amy Vandekop, Controller, effective 2026-07-27
As a result, on July 16, 2026, the Board designated Amy Vandekop, the Company's Corporate Controller, as the Company's interim principal accounting officer, effective as of July 27, 2026.
Appointed: Laurie Keating, Director, effective 2026-08-01
On July 3, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board elected Laurie Keating to serve as a member of the Board, effective as of August 1, 2026.
Appointed: Laurie Keating, effective 2026-08-01
The Board also elected Ms. Keating to serve as a member of the Audit Committee, effective as of August 1, 2026.
Departing: Matthew Gall, Chief Financial Officer, effective 2026-04-14
On April 8, 2026, Matthew Gall notified Kalaris Therapeutics, Inc. (the "Company") of his decision to resign as the Chief Financial Officer of the Company, effective April 14, 2026 (the "Separation Date").
Find people with the same kind of experience as the Chief Financial Officer at Kalaris Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Kalaris Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Kalaris Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Kalaris Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Kalaris Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.